The role of galectin‐3 in heart failure and cardiovascular disease

Summary Galectin‐3, a β‐galactoside‐binding lectin, is a new important player in the progression of heart failure (HF) and is also linked to poor outcome in patients with cardiovascular disease. Genetic or pharmacological inhibition of galectin‐3 slows down the progression of myocardial inflammation...

Full description

Saved in:
Bibliographic Details
Published inClinical and experimental pharmacology & physiology Vol. 46; no. 3; pp. 197 - 203
Main Authors Zhong, Xiao, Qian, Xiaoqian, Chen, Guangping, Song, Xiang
Format Journal Article
LanguageEnglish
Published Australia Wiley Subscription Services, Inc 01.03.2019
Subjects
aldosterone
angiotenin II
Animals
Cardiovascular disease
Cardiovascular diseases
Collagen
Congestive heart failure
Coronary artery disease
Fibrosis
Galectin 3 - metabolism
galectin‐3
Heart failure
Heart Failure - diagnosis
Heart Failure - metabolism
Heart Failure - pathology
Heart Failure - therapy
Humans
Pharmacology
Risk Assessment
angiotenin II
cardiovascular disease
fibrosis
galectin-3
aldosterone
Online AccessGet full text
ISSN0305-1870
1440-1681
1440-1681
DOI10.1111/1440-1681.13048

Cover

Abstract Summary Galectin‐3, a β‐galactoside‐binding lectin, is a new important player in the progression of heart failure (HF) and is also linked to poor outcome in patients with cardiovascular disease. Genetic or pharmacological inhibition of galectin‐3 slows down the progression of myocardial inflammation, reduces collagen production, attenuates cardiac remodelling, and ameliorates cardiac function. In this review, we summarize recent progress in research on galectin‐3 as a regulatory molecule involved in cardiovascular fibrosis in HF and its potential role in the diagnosis, risk assessment and treatment of cardiovascular diseases.
AbstractList Galectin-3, a β-galactoside-binding lectin, is a new important player in the progression of heart failure (HF) and is also linked to poor outcome in patients with cardiovascular disease. Genetic or pharmacological inhibition of galectin-3 slows down the progression of myocardial inflammation, reduces collagen production, attenuates cardiac remodelling, and ameliorates cardiac function. In this review, we summarize recent progress in research on galectin-3 as a regulatory molecule involved in cardiovascular fibrosis in HF and its potential role in the diagnosis, risk assessment and treatment of cardiovascular diseases.
Galectin‐3, a β‐galactoside‐binding lectin, is a new important player in the progression of heart failure ( HF ) and is also linked to poor outcome in patients with cardiovascular disease. Genetic or pharmacological inhibition of galectin‐3 slows down the progression of myocardial inflammation, reduces collagen production, attenuates cardiac remodelling, and ameliorates cardiac function. In this review, we summarize recent progress in research on galectin‐3 as a regulatory molecule involved in cardiovascular fibrosis in HF and its potential role in the diagnosis, risk assessment and treatment of cardiovascular diseases.
Summary Galectin‐3, a β‐galactoside‐binding lectin, is a new important player in the progression of heart failure (HF) and is also linked to poor outcome in patients with cardiovascular disease. Genetic or pharmacological inhibition of galectin‐3 slows down the progression of myocardial inflammation, reduces collagen production, attenuates cardiac remodelling, and ameliorates cardiac function. In this review, we summarize recent progress in research on galectin‐3 as a regulatory molecule involved in cardiovascular fibrosis in HF and its potential role in the diagnosis, risk assessment and treatment of cardiovascular diseases.
Galectin-3, a β-galactoside-binding lectin, is a new important player in the progression of heart failure (HF) and is also linked to poor outcome in patients with cardiovascular disease. Genetic or pharmacological inhibition of galectin-3 slows down the progression of myocardial inflammation, reduces collagen production, attenuates cardiac remodelling, and ameliorates cardiac function. In this review, we summarize recent progress in research on galectin-3 as a regulatory molecule involved in cardiovascular fibrosis in HF and its potential role in the diagnosis, risk assessment and treatment of cardiovascular diseases.Galectin-3, a β-galactoside-binding lectin, is a new important player in the progression of heart failure (HF) and is also linked to poor outcome in patients with cardiovascular disease. Genetic or pharmacological inhibition of galectin-3 slows down the progression of myocardial inflammation, reduces collagen production, attenuates cardiac remodelling, and ameliorates cardiac function. In this review, we summarize recent progress in research on galectin-3 as a regulatory molecule involved in cardiovascular fibrosis in HF and its potential role in the diagnosis, risk assessment and treatment of cardiovascular diseases.
Author Zhong, Xiao
Chen, Guangping
Qian, Xiaoqian
Song, Xiang
Author_xml – sequence: 1
  givenname: Xiao
  orcidid: 0000-0003-2883-3664
  surname: Zhong
  fullname: Zhong, Xiao
  organization: Harbin Medical University
– sequence: 2
  givenname: Xiaoqian
  surname: Qian
  fullname: Qian, Xiaoqian
  organization: Shanghai Jiao Tong University School of Medicine
– sequence: 3
  givenname: Guangping
  surname: Chen
  fullname: Chen, Guangping
  organization: Emory University School of Medicine
– sequence: 4
  givenname: Xiang
  surname: Song
  fullname: Song, Xiang
  email: song761231@sina.com
  organization: Harbin Medical University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30372548$$D View this record in MEDLINE/PubMed
BookMark eNqFkb9OHDEQxi1EBAdJTRdZokmzMP539pboIICElBSktnz2LBjtrYm9m4iOR8gz5knwcUBBwzQjjX7fzKdv9sj2kAYk5IDBEat1zKSEhs0NO2ICpNkis7fJNpmBANUwo2GX7JVyBwAK5mKH7AoQmitpZuT0-hZpTj3S1NEb16Mf4_D_8Z-gcaC36PJIOxf7KSN1Q6De5RDTH1f81LtMQyzoCn4mnzrXF_zy0vfJr-9n14uL5urH-eXi5KrxUmjTcK1RqM5wr4PTkikJXppgvJPCc93qlleL2nnF9dKHVmrA4MOyXXZScePFPvm22Xuf0-8Jy2hXsXjsezdgmorljGsODNS8oofv0Ls05aG6q5QRjBmAtlJfX6hpucJg73NcufxgX_OpwPEG8DmVkrF7QxjY9QfsOm-7zts-f6Aq1DuFj6MbYxrGXIP8WPc39vjw0Rm7OPu50T0BjSyVuA
CitedBy_id crossref_primary_10_3390_diagnostics11050824
crossref_primary_10_1016_j_ijcard_2024_132955
crossref_primary_10_1016_j_cyto_2022_155970
crossref_primary_10_3389_fimmu_2024_1395714
crossref_primary_10_3390_metabo12040316
crossref_primary_10_3390_biomedicines10051085
crossref_primary_10_2478_eabr_2024_0060
crossref_primary_10_1111_apha_13784
crossref_primary_10_7554_eLife_66921
crossref_primary_10_1002_ccd_29067
crossref_primary_10_2174_1573403X19666230320165821
crossref_primary_10_1161_ATVBAHA_121_317365
crossref_primary_10_34067_KID_0000000000000198
crossref_primary_10_1016_j_sleep_2024_09_016
crossref_primary_10_1177_15353702231198080
crossref_primary_10_1093_clinchem_hvaa228
crossref_primary_10_3390_biom10091277
crossref_primary_10_3390_cells13171471
crossref_primary_10_17116_labs2024130315
crossref_primary_10_3389_fimmu_2020_01321
crossref_primary_10_1038_s41598_021_98227_x
crossref_primary_10_2174_0109298665301698240404061300
crossref_primary_10_1016_j_heares_2022_108602
crossref_primary_10_1177_15353702231151980
crossref_primary_10_21931_RB_CSS_2023_08_01_14
crossref_primary_10_1038_s41440_023_01231_z
crossref_primary_10_1007_s00392_021_01898_9
crossref_primary_10_3390_app11104397
crossref_primary_10_3390_jcm10225364
crossref_primary_10_1038_s41573_023_00636_2
crossref_primary_10_20538_1682_0363_2021_3_72_78
crossref_primary_10_1017_S1047951123000331
crossref_primary_10_1007_s10741_019_09858_2
crossref_primary_10_7759_cureus_53445
crossref_primary_10_1080_13813455_2024_2387710
crossref_primary_10_3389_fphys_2023_1304735
crossref_primary_10_3390_ijms232415554
crossref_primary_10_1007_s12265_022_10285_2
crossref_primary_10_1016_j_cytogfr_2021_10_006
crossref_primary_10_3389_fcvm_2021_748875
crossref_primary_10_1007_s00109_021_02099_7
crossref_primary_10_15829_1728_8800_2023_3416
crossref_primary_10_1016_j_mehy_2022_110964
crossref_primary_10_1155_2019_3632906
crossref_primary_10_1186_s12947_022_00272_7
crossref_primary_10_1002_ehf2_14151
crossref_primary_10_1016_j_exer_2020_108120
crossref_primary_10_4049_jimmunol_1900212
crossref_primary_10_1016_j_numecd_2022_03_001
crossref_primary_10_3238_PersDia_2022_01_21_03
crossref_primary_10_3390_cells11162531
crossref_primary_10_1016_j_biopha_2020_111066
crossref_primary_10_21303_2504_5679_2020_001409
crossref_primary_10_1111_cns_70127
crossref_primary_10_1016_j_biopha_2021_112178
crossref_primary_10_3390_biom13020395
crossref_primary_10_1371_journal_pone_0229462
crossref_primary_10_1186_s13578_021_00592_7
crossref_primary_10_1016_j_trim_2024_102159
crossref_primary_10_1002_jbt_22717
crossref_primary_10_1111_bph_15719
Cites_doi 10.1161/01.CIR.99.3.384
10.1083/jcb.200108062
10.1046/j.1432-1327.1999.00671.x
10.1016/j.jacc.2006.03.061
10.1161/01.HYP.33.4.981
10.1161/CIRCHEARTFAILURE.116.003804
10.1152/ajpheart.00305.2007
10.1161/ATVBAHA.111.240309
10.1007/s003359900548
10.1038/labinvest.2008.111
10.1006/abbi.1997.0447
10.1016/j.ijcard.2013.12.129
10.1073/pnas.84.18.6452
10.1016/j.jchf.2014.12.009
10.1016/0092-8674(94)90498-7
10.2353/ajpath.2007.060906
10.1038/nrcardio.2010.165
10.1016/j.atherosclerosis.2016.06.002
10.1016/j.yjmcc.2013.07.010
10.3389/fphar.2016.00495
10.1152/ajpheart.00142.2002
10.1016/S0304-4165(97)00086-X
10.1097/00005344-200306000-00006
10.1161/HYPERTENSIONAHA.115.06161
10.1016/j.bbagen.2005.12.020
10.1073/pnas.92.4.1213
10.1074/jbc.273.21.13047
10.1093/glycob/cwn104
10.1161/HYPERTENSIONAHA.115.05876
10.1016/j.amjcard.2014.05.062
10.1517/14656566.5.9.1957
10.1152/ajpheart.00747.2008
10.1016/j.ijcard.2017.12.103
10.1016/j.ijcard.2014.08.011
10.1136/hrt.65.5.245
10.1016/j.jash.2017.03.008
10.1111/j.1365-3083.2007.01986.x
10.1161/HYPERTENSIONAHA.111.190512
10.1002/aja.1002030211
10.1152/physiol.00009.2012
10.1136/ard.2006.066514
10.1016/j.jchf.2014.08.002
10.1111/bph.12825
10.1091/mbc.E04-12-1119
10.1007/s12253-013-9603-7
10.1074/jbc.M200154200
10.1007/s10555-007-9095-6
10.1016/j.ejheart.2008.08.005
10.1080/08037050902843726
10.7150/thno.22196
10.1016/j.bbamcr.2014.12.001
10.1016/j.ijcard.2011.05.081
10.1023/A:1021106232511
10.1111/j.1365-2796.2011.02476.x
10.1016/j.bcp.2008.02.003
10.1042/CS20171389
10.1016/S0021-9258(18)82422-X
10.1016/j.jacc.2012.04.053
10.1016/j.placenta.2006.07.005
10.1136/jim-2015-000014
10.1517/14656566.5.6.1279
10.1161/ATVBAHA.112.300569
10.1161/01.CIR.0000091084.46500.BB
10.1161/01.CIR.0000147181.65298.4D
10.1017/S1462399408000719
10.1161/CIRCHEARTFAILURE.112.971168
10.4049/jimmunol.128.3.1221
10.1056/NEJMra021498
10.1161/JAHA.112.004374
10.4049/jimmunol.180.4.2650
10.1016/j.jchf.2014.07.015
10.1152/ajprenal.00498.2012
10.1016/j.ijcard.2015.02.008
10.1371/journal.pone.0095254
10.1038/nm1000
10.1093/nar/29.17.3595
ContentType Journal Article
Copyright 2018 John Wiley & Sons Australia, Ltd
2018 John Wiley & Sons Australia, Ltd.
Copyright © 2019 John Wiley & Sons Australia, Ltd
Copyright_xml – notice: 2018 John Wiley & Sons Australia, Ltd
– notice: 2018 John Wiley & Sons Australia, Ltd.
– notice: Copyright © 2019 John Wiley & Sons Australia, Ltd
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7TK
7U7
C1K
7X8
DOI 10.1111/1440-1681.13048
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Toxicology Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Toxicology Abstracts
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList MEDLINE
CrossRef
Toxicology Abstracts

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Pharmacy, Therapeutics, & Pharmacology
EISSN 1440-1681
EndPage 203
ExternalDocumentID 30372548
10_1111_1440_1681_13048
CEP13048
Genre reviewArticle
Research Support, Non-U.S. Gov't
Journal Article
Review
GrantInformation_xml – fundername: Chinese National Natural Science Foundation
  funderid: 81300248; 81570358
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1OB
1OC
29B
2QV
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAKAS
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACUHS
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHEFC
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DC6
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
DXH
EAD
EAP
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
GWYGA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
KTM
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK0
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOQ
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
XG1
YCJ
YFH
YUY
ZGI
ZXP
ZZTAW
~IA
~WT
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7TK
7U7
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
C1K
7X8
ID FETCH-LOGICAL-c4378-277e35f82c7da741540c48d8ca43c2797920007ac527bcd9470edcdb9bf4528c3
IEDL.DBID DR2
ISSN 0305-1870
1440-1681
IngestDate Fri Jul 11 01:40:50 EDT 2025
Sun Jul 13 04:25:09 EDT 2025
Thu Apr 03 07:03:00 EDT 2025
Tue Jul 01 02:11:07 EDT 2025
Thu Apr 24 23:04:23 EDT 2025
Wed Jan 22 17:09:21 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords angiotenin II
cardiovascular disease
fibrosis
galectin-3
aldosterone
Language English
License 2018 John Wiley & Sons Australia, Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4378-277e35f82c7da741540c48d8ca43c2797920007ac527bcd9470edcdb9bf4528c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0003-2883-3664
PMID 30372548
PQID 2183118009
PQPubID 2029980
PageCount 7
ParticipantIDs proquest_miscellaneous_2127201056
proquest_journals_2183118009
pubmed_primary_30372548
crossref_primary_10_1111_1440_1681_13048
crossref_citationtrail_10_1111_1440_1681_13048
wiley_primary_10_1111_1440_1681_13048_CEP13048
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate March 2019
PublicationDateYYYYMMDD 2019-03-01
PublicationDate_xml – month: 03
  year: 2019
  text: March 2019
PublicationDecade 2010
PublicationPlace Australia
PublicationPlace_xml – name: Australia
– name: Richmond
PublicationTitle Clinical and experimental pharmacology & physiology
PublicationTitleAlternate Clin Exp Pharmacol Physiol
PublicationYear 2019
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2009; 89
2015; 184
2012; 60
1998; 1379
1991; 51
2002; 277
2002; 156
2013; 63
2004; 5
2006; 1760
2014; 172
2008; 75
2012; 59
1998; 82
2014; 176
2011; 150
2013; 6
1997; 8
1998; 273
2007; 28
2013; 19
2018; 8
2018; 132
2015; 172
1987; 84
2013; 17
2007; 171
2018; 258
1995; 203
2008; 67
1999; 99
2012; 27
2014; 9
2009; 19
2007; 66
2003; 41
2003; 242
1994; 76
2007; 26
2009; 18
2003; 284
1995; 92
2015; 3
1982; 128
2013; 305
1999; 264
2008; 10
2015; 1853
2009; 296
2001; 29
1993; 268
2011; 8
2012; 32
2014; 114
2004; 10
2008; 180
2012; 272
2004; 110
2016; 7
2003; 108
2003; 348
2012; 1
2013; 33
1991; 65
2017; 11
2017; 10
2015; 66
2006; 48
1998; 349
2016; 64
1999; 33
2005; 16
2016; 251
2008; 294
2016; 23
2016; 67
e_1_2_12_4_1
e_1_2_12_6_1
e_1_2_12_19_1
e_1_2_12_2_1
e_1_2_12_17_1
e_1_2_12_38_1
e_1_2_12_20_1
e_1_2_12_41_1
e_1_2_12_66_1
e_1_2_12_22_1
e_1_2_12_43_1
e_1_2_12_64_1
e_1_2_12_24_1
e_1_2_12_45_1
Toprak G (e_1_2_12_80_1) 2013; 17
e_1_2_12_26_1
e_1_2_12_47_1
e_1_2_12_68_1
e_1_2_12_62_1
e_1_2_12_60_1
e_1_2_12_81_1
Ho MK (e_1_2_12_12_1) 1982; 128
Raz A (e_1_2_12_13_1) 1991; 51
e_1_2_12_28_1
e_1_2_12_49_1
e_1_2_12_31_1
e_1_2_12_52_1
Clarke DE (e_1_2_12_73_1) 1998; 82
e_1_2_12_77_1
e_1_2_12_54_1
e_1_2_12_75_1
e_1_2_12_35_1
e_1_2_12_56_1
e_1_2_12_37_1
e_1_2_12_58_1
e_1_2_12_79_1
e_1_2_12_14_1
Agrwal N (e_1_2_12_16_1) 1993; 268
e_1_2_12_8_1
e_1_2_12_10_1
e_1_2_12_50_1
e_1_2_12_71_1
e_1_2_12_3_1
e_1_2_12_5_1
e_1_2_12_18_1
e_1_2_12_39_1
e_1_2_12_42_1
e_1_2_12_65_1
e_1_2_12_21_1
e_1_2_12_44_1
e_1_2_12_63_1
e_1_2_12_23_1
e_1_2_12_46_1
e_1_2_12_69_1
e_1_2_12_25_1
e_1_2_12_48_1
e_1_2_12_67_1
e_1_2_12_61_1
e_1_2_12_40_1
e_1_2_12_27_1
e_1_2_12_29_1
e_1_2_12_30_1
e_1_2_12_53_1
e_1_2_12_76_1
e_1_2_12_32_1
e_1_2_12_55_1
e_1_2_12_74_1
e_1_2_12_34_1
e_1_2_12_57_1
e_1_2_12_36_1
e_1_2_12_59_1
e_1_2_12_78_1
e_1_2_12_15_1
Cardoso AC (e_1_2_12_33_1) 2016; 23
e_1_2_12_11_1
e_1_2_12_72_1
e_1_2_12_7_1
e_1_2_12_51_1
e_1_2_12_70_1
e_1_2_12_9_1
References_xml – volume: 132
  start-page: 1471
  issue: 13
  year: 2018
  end-page: 1485
  article-title: Galectin‐3 down‐regulates antioxidant peroxiredoxin‐4 in human cardiac fibroblasts: a new pathway to induce cardiac damage
  publication-title: Clin Sci
– volume: 251
  start-page: 94
  year: 2016
  end-page: 100
  article-title: Galectin‐3 binding protein plasma levels are associated with long‐term mortality in coronary artery disease independent of plaque morphology
  publication-title: Atherosclerosis
– volume: 26
  start-page: 605
  issue: 3–4
  year: 2007
  end-page: 610
  article-title: Regulation of cancer‐related gene expression by galectin‐3 and the molecular mechanism of its nuclear import pathway
  publication-title: Cancer Metastasis Rev
– volume: 51
  start-page: 2173
  issue: 8
  year: 1991
  end-page: 2178
  article-title: Molecular cloning and chromosomal mapping of a human galactoside‐binding protein
  publication-title: Cancer Res
– volume: 171
  start-page: 463
  issue: 2
  year: 2007
  end-page: 472
  article-title: Interferon‐gamma induces chronic active myocarditis and cardiomyopathy in transgenic mice
  publication-title: Am J Pathol
– volume: 27
  start-page: 130
  issue: 3
  year: 2012
  end-page: 139
  article-title: Cardiac actions of protein kinase C isoforms
  publication-title: Physiology (Bethesda)
– volume: 8
  start-page: 30
  issue: 1
  year: 2011
  end-page: 41
  article-title: Epidemiology and risk profile of heart failure
  publication-title: Nat Rev Cardiol
– volume: 99
  start-page: 384
  issue: 3
  year: 1999
  end-page: 391
  article-title: Increased protein kinase C activity and expression of Ca2 + ‐sensitive isoforms in the failing human heart
  publication-title: Circulation
– volume: 156
  start-page: 905
  issue: 5
  year: 2002
  end-page: 919
  article-title: PKC alpha regulates the hypertrophic growth of cardiomyocytes through extracellular signal‐regulated kinase1/2 (ERK1/2)
  publication-title: J Cell Biol
– volume: 11
  start-page: 275
  issue: 5
  year: 2017
  end-page: 289
  article-title: Galectin‐3 mediates the pulmonary arterial hypertension‐induced right ventricular remodeling through interacting with NADPH oxidase 4
  publication-title: J Am Soc Hypertens
– volume: 1853
  start-page: 513
  issue: 2
  year: 2015
  end-page: 521
  article-title: Protein kinase C promotes cardiac fibrosis and heart failure by modulating galectin‐3 expression
  publication-title: Biochim Biophys Acta
– volume: 172
  start-page: 1494
  issue: 6
  year: 2015
  end-page: 1504
  article-title: Exogenous administration of thiosulfate, a donor of hydrogen sulfide, attenuates angiotensin II‐induced hypertensive heart disease in rats
  publication-title: Br J Pharmacol
– volume: 17
  start-page: 2302
  year: 2013
  end-page: 2309
  article-title: Fibrosis in heart failure subtypes
  publication-title: Eur Rev Med Pharmacol Sci
– volume: 10
  start-page: e17
  year: 2008
  article-title: Galectins: structure, function and therapeutic potential
  publication-title: Expert Rev Mol Med
– volume: 1
  start-page: e004374
  issue: 5
  year: 2012
  article-title: Galectin‐3 in heart failure: more answers or more questions?
  publication-title: J Am Heart Assoc
– volume: 305
  start-page: F90
  issue: 1
  year: 2013
  end-page: F99
  article-title: Galectin‐3 mediates oligomerization of secreted hensin using its carbohydrate‐recognition domain
  publication-title: Am J Physiol Renal Physiol
– volume: 176
  start-page: 1423
  issue: 3
  year: 2014
  end-page: 1425
  article-title: Galectin‐3 is essential for early wound healing and ventricular remodeling after myocardial infarction in mice
  publication-title: Int J Cardiol
– volume: 349
  start-page: 7
  issue: 1
  year: 1998
  end-page: 20
  article-title: The human LGALS3 (galectin‐3) gene: determination of the gene structure and functional characterization of the promoter
  publication-title: Arch Biochem Biophys
– volume: 10
  start-page: e003804
  year: 2017
  article-title: Plasma and cardiac galectin‐3 in patients with heart failure reflects both inflammation and fibrosis: implications for its use as a biomarker
  publication-title: Circ Heart Fail
– volume: 92
  start-page: 1213
  year: 1995
  end-page: 1217
  article-title: Identification of galectin‐3 as a factor in pre‐mRNA splicing
  publication-title: Proc Natl Acad Sci USA
– volume: 172
  start-page: e98
  issue: 1
  year: 2014
  end-page: e101
  article-title: Galectin‐3 expression in cardiac remodeling after myocardial infarction
  publication-title: Int J Cardiol
– volume: 184
  start-page: 96
  year: 2015
  end-page: 100
  article-title: Galectin‐3 and myocardial fibrosis in nonischemic dilated cardiomyopathy
  publication-title: Int J Cardiol
– volume: 66
  start-page: 767
  issue: 4
  year: 2015
  end-page: 775
  article-title: Galectin‐3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension
  publication-title: Hypertension
– volume: 114
  start-page: 737
  issue: 5
  year: 2014
  end-page: 742
  article-title: Effect of spironolactone on 30‐day death and heart failure rehospitalization (from the COACH Study)
  publication-title: Am J Cardiol
– volume: 19
  start-page: 461
  issue: 3
  year: 2013
  end-page: 474
  article-title: Galectin‐3 accelerates the progression of oral tongue squamous cell carcinoma via a Wnt/β‐catenin‐dependent pathway
  publication-title: Pathol Oncol Res
– volume: 3
  start-page: 253
  issue: 3
  year: 2015
  end-page: 256
  article-title: Evolving role of galectin‐3 as a cardiac biomarker: heart failure with preserved ejection fraction and renal function, important pieces of the puzzle
  publication-title: JACC Heart Fail
– volume: 28
  start-page: 399
  issue: 5–6
  year: 2007
  end-page: 407
  article-title: Proteomic analysis of hypoxia‐induced responses in the syncytialization of human placental cell line BeWo
  publication-title: Placenta
– volume: 29
  start-page: 3595
  issue: 17
  year: 2001
  end-page: 3602
  article-title: Association of galectin‐1 and galectin‐3 with Gemin4 in complexes containing the SMN protein
  publication-title: Nucleic Acids Res
– volume: 180
  start-page: 2650
  year: 2008
  end-page: 2658
  article-title: Regulation of alternative macrophage activation by Galectin‐3.
  publication-title: J Immunol
– volume: 108
  start-page: 1567
  issue: 13
  year: 2003
  end-page: 1574
  article-title: Oxygen free radical release in human failing myocardium is associated with increased activity of rac1‐GTPase and represents a target for statin treatment
  publication-title: Circulation
– volume: 84
  start-page: 6452
  issue: 18
  year: 1987
  end-page: 6456
  article-title: Endogenous lectins from cultured cells: nuclear localization of carbohydrate‐binding protein 35 in proliferating 3T3 fibroblasts
  publication-title: Proc Natl Acad Sci USA
– volume: 3
  start-page: 50
  issue: 1
  year: 2015
  end-page: 58
  article-title: Mineralocorticoid receptor antagonists modulate galectin‐3 and interleukin‐33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction
  publication-title: JACC Heart Fail
– volume: 272
  start-page: 55
  issue: 1
  year: 2012
  end-page: 64
  article-title: The fibrosis marker galectin‐3 and outcome in the general population
  publication-title: J Intern Med
– volume: 9
  start-page: e95254
  issue: 9
  year: 2014
  article-title: Aldosterone induced galectin‐3 secretion in vitro and in vivo: from cells to humans
  publication-title: PLoS ONE
– volume: 76
  start-page: 597
  issue: 4
  year: 1994
  end-page: 598
  article-title: Galectins: a family of animal beta‐galactoside‐binding lectins
  publication-title: Cell
– volume: 63
  start-page: 98
  year: 2013
  end-page: 106
  article-title: Impact of the renin‐angiotensin system on cardiac energy metabolism in heart failure
  publication-title: J Mol Cell Cardiol
– volume: 3
  start-page: 59
  issue: 1
  year: 2015
  end-page: 67
  article-title: The impact of galectin‐3 inhibition on aldosterone‐induced cardiac and renal injuries
  publication-title: JACC Heart Fail
– volume: 203
  start-page: 241
  issue: 2
  year: 1995
  end-page: 251
  article-title: Galectin‐3 is expressed in the notochord, developing bones, and skin of the postimplantation mouse embryo
  publication-title: Dev Dyn
– volume: 32
  start-page: 894
  issue: 4
  year: 2012
  end-page: 901
  article-title: Identification of galectin‐1 and galectin‐3 as novel partners for von Willebrand factor
  publication-title: Arterioscler Thromb Vasc Biol
– volume: 10
  start-page: 248
  issue: 3
  year: 2004
  end-page: 254
  article-title: PKC‐alpha regulates cardiac contractility and propensity toward heart failure
  publication-title: Nat Med
– volume: 82
  start-page: 167
  issue: 1
  year: 1998
  article-title: Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia: past, present and future
  publication-title: Br J Urol
– volume: 6
  start-page: 107
  issue: 1
  year: 2013
  end-page: 117
  article-title: Genetic and pharmacological inhibition of galectin‐3 prevents cardiac remodeling by interfering with myocardial fibrogenesis
  publication-title: Circ Heart Fail
– volume: 18
  start-page: 74
  issue: 1–2
  year: 2009
  end-page: 77
  article-title: Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension
  publication-title: Blood Press
– volume: 48
  start-page: 1217
  issue: 6
  year: 2006
  end-page: 1224
  article-title: Utility of amino‐terminal pro‐brain natriuretic peptide, galectin‐3, and apelin for the evaluation of patients with acute heart failure
  publication-title: J Am Coll Cardiol
– volume: 258
  start-page: 217
  year: 2018
  end-page: 223
  article-title: A role for fumarate hydratase in mediating oxidative effects of galectin‐3 in human cardiac fibroblasts
  publication-title: Int J Cardiol
– volume: 67
  start-page: 606
  issue: 3
  year: 2016
  end-page: 612
  article-title: Inhibition of galectin‐3 pathway prevents isoproterenol‐induced left ventricular dysfunction and fibrosis in mice
  publication-title: Hypertension
– volume: 294
  start-page: H1226
  issue: 3
  year: 2008
  end-page: H1232
  article-title: Novel anti‐inflammatory mechanisms of N‐Acetyl‐Ser‐Asp‐Lys‐Pro in hypertension‐induced target organ damage
  publication-title: Am J Physiol Heart Circ Physiol
– volume: 64
  start-page: 1109
  issue: 6
  year: 2016
  end-page: 1113
  article-title: The relation among aldosterone, galectin‐3, and myocardial fibrosis: a prospective clinical pilot follow‐up study
  publication-title: J Investig Med
– volume: 5
  start-page: 1957
  issue: 9
  year: 2004
  end-page: 1964
  article-title: After ALLHAT: doxazosin for the treatment of benign prostatic hyperplasia
  publication-title: Expert Opin Pharmacother
– volume: 67
  start-page: 175
  issue: 2
  year: 2008
  end-page: 181
  article-title: Intracellular localisation of galectin‐3 has a protective role in chondrocyte survival
  publication-title: Ann Rheum Dis
– volume: 8
  start-page: 706
  year: 1997
  end-page: 707
  article-title: Mapping of the galectin‐3 gene (LGALS3) to human chromosome 14 at region 14q21‐22
  publication-title: Mamm Genome
– volume: 1760
  start-page: 616
  issue: 4
  year: 2006
  end-page: 635
  article-title: Galectin‐3: an open‐ended story
  publication-title: Biochim Biophys Acta
– volume: 19
  start-page: 16
  issue: 1
  year: 2009
  end-page: 20
  article-title: Galectin‐3 functions as an opsonin and enhances the macrophage clearance of apoptotic neutrophils
  publication-title: Glycobiology
– volume: 16
  start-page: 3028
  issue: 6
  year: 2005
  end-page: 3039
  article-title: Galectin‐3 is a downstream regulator of matrix metalloproteinase‐9 function during endochondral bone formation
  publication-title: Mol Biol Cell
– volume: 296
  start-page: H404
  issue: 2
  year: 2009
  end-page: H412
  article-title: N‐acetyl‐seryl‐aspartyl‐lysyl‐proline prevents cardiac remodeling and dysfunction induced by galectin‐3, a mammalian adhesion/growth‐regulatory lectin
  publication-title: Am J Physiol Heart Circ Physiol
– volume: 128
  start-page: 1221
  issue: 3
  year: 1982
  end-page: 1228
  article-title: Mac‐2, a novel 32,000 Mr mouse macrophage subpopulation‐specific antigen defined by monoclonal antibodies
  publication-title: J Immunol
– volume: 75
  start-page: 1797
  issue: 9
  year: 2008
  end-page: 1806
  article-title: 14‐3‐3 protein regulates Ask1 signaling and protects against diabetic cardiomyopathy
  publication-title: Biochem Pharmacol
– volume: 59
  start-page: 1179
  issue: 6
  year: 2012
  end-page: 1187
  article-title: Aldosterone inhibits antifibrotic factors in mouse hypertensive heart
  publication-title: Hypertension
– volume: 242
  start-page: 145
  issue: 1–2
  year: 2003
  end-page: 152
  article-title: Alterations in protein kinase C isoenzyme expression and autophosphorylation during the progression of pressure overload‐induced left ventricular hypertrophy
  publication-title: Mol Cell Biochem
– volume: 60
  start-page: 1249
  issue: 14
  year: 2012
  end-page: 1256
  article-title: Galectin‐3, a marker of cardiac fibrosis, predicts incident heart failure in the community
  publication-title: J Am Coll Cardiol
– volume: 8
  start-page: 593
  issue: 3
  year: 2018
  end-page: 609
  article-title: Galectin‐3 activation and inhibition in heart failure and cardiovascular disease: an update
  publication-title: Theranostics
– volume: 268
  start-page: 14932
  issue: 20
  year: 1993
  end-page: 14939
  article-title: Carbohydrate‐binding protein 35. I. Properties of the recombinant polypeptide and the individuality of the domains
  publication-title: J Biol Chem
– volume: 110
  start-page: 3121
  issue: 19
  year: 2004
  end-page: 3128
  article-title: Galectin‐3 marks activated macrophages in failure‐prone hypertrophied hearts and contributes to cardiac dysfunction
  publication-title: Circulation
– volume: 41
  start-page: 866
  year: 2003
  end-page: 869
  article-title: Doxazosin as combination therapy for patients with stage 1 and stage 2 hypertension
  publication-title: J Cardiovasc Pharmacol
– volume: 273
  start-page: 13047
  year: 1998
  end-page: 13052
  article-title: X‐ray crystal structure of the human galectin‐3 carbohydrate recognition domain at 2.1‐A resolution
  publication-title: J Biol Chem
– volume: 65
  start-page: 245
  year: 1991
  end-page: 248
  article-title: Oxygen free radicals and congestive Source
  publication-title: Br Heart J
– volume: 5
  start-page: 1279
  issue: 6
  year: 2004
  end-page: 1285
  article-title: The role of alpha‐blockers in the management of prostate cancer
  publication-title: Expert Opin Pharmacother
– volume: 7
  start-page: 495
  year: 2016
  article-title: Doxazosin stimulates galectin‐3 expression and collagen synthesis in HL‐1 cardiomyocytes independent of protein kinase C pathway
  publication-title: Front Pharmacol
– volume: 66
  start-page: 143
  issue: 2–3
  year: 2007
  end-page: 158
  article-title: An emerging role for galectins in tuning the immune response: lessons from experimental models of inflammatory disease, autoimmunity and cancer
  publication-title: Scand J Immunol
– volume: 348
  start-page: 2007
  year: 2003
  end-page: 2018
  article-title: Heart failure
  publication-title: N Engl J Med
– volume: 23
  start-page: 127
  issue: 6
  year: 2016
  article-title: Galectin‐3 determines tumor cell adaptive strategies in stressed tumor microenvironments
  publication-title: Front Oncol
– volume: 284
  start-page: H2277
  issue: 6
  year: 2003
  end-page: H2287
  article-title: Increased expression of protein kinase C isoforms in heart failure due to myocardial infarction
  publication-title: Am J Physiol Heart Circ Physiol
– volume: 264
  start-page: 569
  issue: 2
  year: 1999
  end-page: 576
  article-title: Determinants in the N‐terminal domains of galectin‐3 for secretion by a novel pathway circumventing the endoplasmic reticulum‐Golgi complex
  publication-title: Eur J Biochem
– volume: 10
  start-page: 933
  issue: 10
  year: 2008
  end-page: 989
  article-title: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)
  publication-title: Eur J Heart Fail
– volume: 150
  start-page: 361
  issue: 3
  year: 2011
  end-page: 364
  article-title: Galectin‐3 in heart failure: high levels are associated with all‐cause mortality
  publication-title: Int J Cardiol
– volume: 277
  start-page: 15819
  issue: 18
  year: 2002
  end-page: 15827
  article-title: Galectin‐3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin‐3 translocation
  publication-title: J Biol Chem
– volume: 33
  start-page: 67
  issue: 1
  year: 2013
  end-page: 75
  article-title: Galectin‐3 mediates aldosterone‐induced vascular fibrosis
  publication-title: Arterioscler Thromb Vasc Biol
– volume: 1379
  start-page: 97
  issue: 1
  year: 1998
  end-page: 106
  article-title: Modulation of the biological functions of galectin‐3 by matrix metalloproteinases
  publication-title: Biochim Biophys Acta
– volume: 89
  start-page: 26
  issue: 1
  year: 2009
  end-page: 37
  article-title: A possible suppressive role of galectin‐3 in upregulated osteoclastogenesis accompanying adjuvant‐induced arthritis in rats
  publication-title: Lab Invest
– volume: 33
  start-page: 981
  issue: 4
  year: 1999
  end-page: 986
  article-title: Angiotensin AT1 receptor subtype as a cardiac target of aldosterone : role in aldosterone‐salt induced fibrosis
  publication-title: Hypertension
– ident: e_1_2_12_63_1
  doi: 10.1161/01.CIR.99.3.384
– ident: e_1_2_12_68_1
  doi: 10.1083/jcb.200108062
– ident: e_1_2_12_36_1
  doi: 10.1046/j.1432-1327.1999.00671.x
– ident: e_1_2_12_77_1
  doi: 10.1016/j.jacc.2006.03.061
– ident: e_1_2_12_53_1
  doi: 10.1161/01.HYP.33.4.981
– volume: 82
  start-page: 167
  issue: 1
  year: 1998
  ident: e_1_2_12_73_1
  article-title: Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia: past, present and future
  publication-title: Br J Urol
– ident: e_1_2_12_5_1
  doi: 10.1161/CIRCHEARTFAILURE.116.003804
– ident: e_1_2_12_42_1
  doi: 10.1152/ajpheart.00305.2007
– ident: e_1_2_12_38_1
  doi: 10.1161/ATVBAHA.111.240309
– ident: e_1_2_12_14_1
  doi: 10.1007/s003359900548
– ident: e_1_2_12_23_1
  doi: 10.1038/labinvest.2008.111
– ident: e_1_2_12_15_1
  doi: 10.1006/abbi.1997.0447
– volume: 51
  start-page: 2173
  issue: 8
  year: 1991
  ident: e_1_2_12_13_1
  article-title: Molecular cloning and chromosomal mapping of a human galactoside‐binding protein
  publication-title: Cancer Res
– ident: e_1_2_12_60_1
  doi: 10.1016/j.ijcard.2013.12.129
– ident: e_1_2_12_22_1
  doi: 10.1073/pnas.84.18.6452
– ident: e_1_2_12_78_1
  doi: 10.1016/j.jchf.2014.12.009
– ident: e_1_2_12_11_1
  doi: 10.1016/0092-8674(94)90498-7
– ident: e_1_2_12_41_1
  doi: 10.2353/ajpath.2007.060906
– ident: e_1_2_12_4_1
  doi: 10.1038/nrcardio.2010.165
– ident: e_1_2_12_34_1
  doi: 10.1016/j.atherosclerosis.2016.06.002
– ident: e_1_2_12_69_1
  doi: 10.1016/j.yjmcc.2013.07.010
– volume: 17
  start-page: 2302
  year: 2013
  ident: e_1_2_12_80_1
  article-title: Fibrosis in heart failure subtypes
  publication-title: Eur Rev Med Pharmacol Sci
– ident: e_1_2_12_10_1
  doi: 10.3389/fphar.2016.00495
– ident: e_1_2_12_65_1
  doi: 10.1152/ajpheart.00142.2002
– ident: e_1_2_12_19_1
  doi: 10.1016/S0304-4165(97)00086-X
– ident: e_1_2_12_71_1
  doi: 10.1097/00005344-200306000-00006
– ident: e_1_2_12_62_1
  doi: 10.1161/HYPERTENSIONAHA.115.06161
– ident: e_1_2_12_27_1
  doi: 10.1016/j.bbagen.2005.12.020
– ident: e_1_2_12_30_1
  doi: 10.1073/pnas.92.4.1213
– volume: 23
  start-page: 127
  issue: 6
  year: 2016
  ident: e_1_2_12_33_1
  article-title: Galectin‐3 determines tumor cell adaptive strategies in stressed tumor microenvironments
  publication-title: Front Oncol
– ident: e_1_2_12_18_1
  doi: 10.1074/jbc.273.21.13047
– ident: e_1_2_12_28_1
  doi: 10.1093/glycob/cwn104
– ident: e_1_2_12_58_1
  doi: 10.1161/HYPERTENSIONAHA.115.05876
– ident: e_1_2_12_54_1
  doi: 10.1016/j.amjcard.2014.05.062
– ident: e_1_2_12_75_1
  doi: 10.1517/14656566.5.9.1957
– ident: e_1_2_12_7_1
  doi: 10.1152/ajpheart.00747.2008
– ident: e_1_2_12_47_1
  doi: 10.1016/j.ijcard.2017.12.103
– ident: e_1_2_12_29_1
  doi: 10.1016/j.ijcard.2014.08.011
– ident: e_1_2_12_50_1
  doi: 10.1136/hrt.65.5.245
– ident: e_1_2_12_51_1
  doi: 10.1016/j.jash.2017.03.008
– ident: e_1_2_12_21_1
  doi: 10.1111/j.1365-3083.2007.01986.x
– ident: e_1_2_12_56_1
  doi: 10.1161/HYPERTENSIONAHA.111.190512
– ident: e_1_2_12_20_1
  doi: 10.1002/aja.1002030211
– ident: e_1_2_12_67_1
  doi: 10.1152/physiol.00009.2012
– ident: e_1_2_12_24_1
  doi: 10.1136/ard.2006.066514
– ident: e_1_2_12_55_1
  doi: 10.1016/j.jchf.2014.08.002
– ident: e_1_2_12_70_1
  doi: 10.1111/bph.12825
– ident: e_1_2_12_37_1
  doi: 10.1091/mbc.E04-12-1119
– ident: e_1_2_12_32_1
  doi: 10.1007/s12253-013-9603-7
– ident: e_1_2_12_26_1
  doi: 10.1074/jbc.M200154200
– ident: e_1_2_12_35_1
  doi: 10.1007/s10555-007-9095-6
– ident: e_1_2_12_3_1
  doi: 10.1016/j.ejheart.2008.08.005
– ident: e_1_2_12_72_1
  doi: 10.1080/08037050902843726
– ident: e_1_2_12_40_1
  doi: 10.7150/thno.22196
– ident: e_1_2_12_9_1
  doi: 10.1016/j.bbamcr.2014.12.001
– ident: e_1_2_12_44_1
  doi: 10.1016/j.ijcard.2011.05.081
– ident: e_1_2_12_64_1
  doi: 10.1023/A:1021106232511
– ident: e_1_2_12_79_1
  doi: 10.1111/j.1365-2796.2011.02476.x
– ident: e_1_2_12_43_1
  doi: 10.1016/j.bcp.2008.02.003
– ident: e_1_2_12_48_1
  doi: 10.1042/CS20171389
– volume: 268
  start-page: 14932
  issue: 20
  year: 1993
  ident: e_1_2_12_16_1
  article-title: Carbohydrate‐binding protein 35. I. Properties of the recombinant polypeptide and the individuality of the domains
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(18)82422-X
– ident: e_1_2_12_45_1
  doi: 10.1016/j.jacc.2012.04.053
– ident: e_1_2_12_25_1
  doi: 10.1016/j.placenta.2006.07.005
– ident: e_1_2_12_57_1
  doi: 10.1136/jim-2015-000014
– ident: e_1_2_12_74_1
  doi: 10.1517/14656566.5.6.1279
– ident: e_1_2_12_61_1
  doi: 10.1161/ATVBAHA.112.300569
– ident: e_1_2_12_49_1
  doi: 10.1161/01.CIR.0000091084.46500.BB
– ident: e_1_2_12_6_1
  doi: 10.1161/01.CIR.0000147181.65298.4D
– ident: e_1_2_12_17_1
  doi: 10.1017/S1462399408000719
– ident: e_1_2_12_8_1
  doi: 10.1161/CIRCHEARTFAILURE.112.971168
– volume: 128
  start-page: 1221
  issue: 3
  year: 1982
  ident: e_1_2_12_12_1
  article-title: Mac‐2, a novel 32,000 Mr mouse macrophage subpopulation‐specific antigen defined by monoclonal antibodies
  publication-title: J Immunol
  doi: 10.4049/jimmunol.128.3.1221
– ident: e_1_2_12_2_1
  doi: 10.1056/NEJMra021498
– ident: e_1_2_12_76_1
  doi: 10.1161/JAHA.112.004374
– ident: e_1_2_12_46_1
  doi: 10.4049/jimmunol.180.4.2650
– ident: e_1_2_12_59_1
  doi: 10.1016/j.jchf.2014.07.015
– ident: e_1_2_12_39_1
  doi: 10.1152/ajprenal.00498.2012
– ident: e_1_2_12_81_1
  doi: 10.1016/j.ijcard.2015.02.008
– ident: e_1_2_12_52_1
  doi: 10.1371/journal.pone.0095254
– ident: e_1_2_12_66_1
  doi: 10.1038/nm1000
– ident: e_1_2_12_31_1
  doi: 10.1093/nar/29.17.3595
SSID ssj0005063
Score 2.4959164
SecondaryResourceType review_article
Snippet Summary Galectin‐3, a β‐galactoside‐binding lectin, is a new important player in the progression of heart failure (HF) and is also linked to poor outcome in...
Galectin‐3, a β‐galactoside‐binding lectin, is a new important player in the progression of heart failure ( HF ) and is also linked to poor outcome in patients...
Galectin-3, a β-galactoside-binding lectin, is a new important player in the progression of heart failure (HF) and is also linked to poor outcome in patients...
Galectin‐3, a β‐galactoside‐binding lectin, is a new important player in the progression of heart failure (HF) and is also linked to poor outcome in patients...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 197
SubjectTerms aldosterone
angiotenin II
Animals
Cardiovascular disease
Cardiovascular diseases
Collagen
Congestive heart failure
Coronary artery disease
Fibrosis
Galectin 3 - metabolism
galectin‐3
Heart failure
Heart Failure - diagnosis
Heart Failure - metabolism
Heart Failure - pathology
Heart Failure - therapy
Humans
Pharmacology
Risk Assessment
Title The role of galectin‐3 in heart failure and cardiovascular disease
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2F1440-1681.13048
https://www.ncbi.nlm.nih.gov/pubmed/30372548
https://www.proquest.com/docview/2183118009
https://www.proquest.com/docview/2127201056
Volume 46
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT9tAEB0hTr1Am1BIm1ZbCaEecOSPtdd7RDQRqlSEEEjcrN31WkKAg5rkEE78hP7G_pLO7NpOA6oQ6i2Sd5P1ZsbzxvvmDcB-GVWx5iYMTB5lAVdCBxgVdYCRNqowHivrKrx_nGYnl_z7VdqyCakWxutDdC_cyDPc85ocXOnZX07uTyWzPKKGxpzKfYmxRbDofCUglTa91BLS20TTbMR9iMvzZP56XHoGNtexqws-k23Q7bI95-RmtJjrkXl4ouj4X_f1FrYaaMqOvC29gw1b96B_VGNafrdkB8yRRd1b-B4cnHnJ6-Uhu1hVcM0O3bBODHvZh294mRGFkU0rRtEIn6_178dfCbuuGXXTnrNKXRM3nqm6ZGaNHsua46MduJyML45PgqZzQ2B4gmlpLIRN0iqPjSgVYRYeGp6XuVE8MbGQQlKFkFAmjYU2peQitKUptdQVT-PcJO9hs57Wdg9YXoWxSRCEZlJyk2bSxiqprE65TktM7Qcwav-3wjSy5tRd47Zo0xva0II2tHAbOoCv3YR7r-jx76HD1hCKxrVnBWFK0s0L5QC-dJfRKemkRdV2uqAxdLyN0DUbwK43oO63EDMIzMrxy70ZvLSI4nh85j58eO2Ej_AGFyE9Y24Im_OfC_sJIdRcf3Ze8gdTPAwS
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB6VcoALhZbHlgKuVFUcmlU2ceL4WPWhBdqqQlupt8ieOFIFZBHdPWxP_Qn8Rn4JM3Y27RahCnGL5EccZ8bzjT3-BmCrGtSJlRhHWAzySBplI7KKNiJLO6jJHhvnb3gfn-TDM_nxPDu_dRcm8EN0G26sGX69ZgXnDelbWh6OJfNiwBmNZfEAHnJeb85isP_5hkIqa7Oppcy4ScLZ0vtwNM-dDhYt0x9wcxG9evNzuAI4H3iIOvnSn05sH6_ucDr-35c9hSctOhW7QZyewZJrVmFttyHP_NtMbAsfL-o34ldh-zSwXs92xOjmEtfljq_W8WHP1mCfigVHMYpxLdgg0RLb_Lr-mYqLRnBC7YmozQWHxwvTVAIXImRFe4L0HM4OD0Z7w6hN3hChTMkzTZRyaVYXCarKMGyRMcqiKtDIFBOlleZLQspgliiLlZYqdhVWVttaZkmB6QtYbsaNewWiqOMEU8KhudYSs1y7xKS1s5m0WUXefQ_68x9XYstszgk2vpZzD4cntOQJLf2E9uB91-B7IPX4e9WNuSSUrXZflgwrmTov1j3Y7IpJL_mwxTRuPOU6fMJN6DXvwcsgQd27CDYocsyp8yAH9w2i3Ds49Q_r_9rgHTwajo6PyqMPJ59ew2MakA4BdBuwPPkxdW8IUU3sW68yvwEiJxAs
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BkRAXCi20CwWMhCoOzSqbOHF8rNquyqtaoVbiFvkpVdBsRXcPy6k_ob-xv4QZO0nZIoQQt0h-xHFmPN_Y428A3tiRzzQ3aWKqUZlwJXSCVlEnaGlHHu2xcuGG96ej8vCEv_9SdNGEdBcm8kP0G26kGWG9JgU_t_4XJY-nkmU1ooTGvLoL93iJKkO46PMNg1TRJlPLiXATZbNl96FgnlsdLBum39DmMngN1me8Crobdww6-Tqcz_TQ_LhF6fhfH_YIHrbYlO1GYXoMd1yzBuu7DfrlZwu2zUK0aNiGX4PtSeS8Xuyw45srXBc7oVrPhr1Yh30sZhTDyKaekTnCBba5vrzK2WnDKJ32jHl1SsHxTDWWmaX4WNaeHz2Bk_HB8d5h0qZuSAzP0S_NhHB54avMCKsItPDU8MpWRvHcZEIKSVeEhDJFJrSxkovUWWO11J4XWWXyp7DSTBu3CazyaWZyRKGllNwUpXSZyr3TBdeFRd9-AMPuv9Wm5TWn9Brf6s6_oQmtaULrMKEDeNs3OI-UHn-uutUJQt3q9kVNoJKI81I5gNd9MWolHbWoxk3nVIfOtxG7lgPYiALUvwtBg0C3HDuPYvC3QdR7B5Pw8OxfG7yC-5P9cf3x3dGH5_AAxyNj9NwWrMy-z90LhFMz_TIozE_rfg7k
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+role+of+galectin-3+in+heart+failure+and+cardiovascular+disease&rft.jtitle=Clinical+and+experimental+pharmacology+%26+physiology&rft.au=Zhong%2C+Xiao&rft.au=Qian%2C+Xiaoqian&rft.au=Chen%2C+Guangping&rft.au=Song%2C+Xiang&rft.date=2019-03-01&rft.eissn=1440-1681&rft.volume=46&rft.issue=3&rft.spage=197&rft_id=info:doi/10.1111%2F1440-1681.13048&rft_id=info%3Apmid%2F30372548&rft.externalDocID=30372548
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0305-1870&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0305-1870&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0305-1870&client=summon